Embecta vs Stevanato Group S.p.A.
EMBC and STVN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EMBC and STVN compare
Stevanato Group S.p.A. grew revenue faster over the last twelve months (7.4% versus −7.6% for Embecta).
Stevanato Group S.p.A. keeps more of each dollar of sales as profit, with a net margin of 11.8% compared with 8.6% at Embecta.
Embecta pays a dividend yielding 5.0%; Stevanato Group S.p.A. does not pay one.
Embecta scores higher on the StockData Score (15 against 8 for Stevanato Group S.p.A.), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EMBC | STVN |
|---|---|---|
| Size and price | ||
| Market cap | $366M | – |
| Share price | $6.46 | $15.80 |
| Change, 1 year | −55.4% | −33.3% |
| Change, 5 years | – | −31.4% |
| Beta (5Y) | 0.68 | 0.95 |
| Employees | 1,850 | 6,010 |
| StockData Score | ||
| Total score | 15 (better) | 8 |
| Valuation score | 6 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 5 (better) | 0 |
| Valuation | ||
| P/E | 4.4× | – |
| P/S | 0.4× | – |
| EV/EBITDA | 6.0× | – |
| P/FCF | 2.2× | – |
| FCF yield | 45.0% | – |
| Fair value | $30.51 | – |
| Margin of safety | 78.8% | – |
| Growth | ||
| Revenue growth (TTM) | −7.6% | 7.4% (better) |
| Revenue growth, 5Y average | −0.09% | 12.4% (better) |
| Net income growth (TTM) | 4.7% | 18.7% (better) |
| EPS growth (TTM) | 2.8% | 18.6% (better) |
| EPS growth, 5Y average | −26.4% | 9.1% (better) |
| Profitability | ||
| Gross margin | 59.0% (better) | 29.0% |
| Operating margin | 21.9% (better) | 16.8% |
| Net margin | 8.6% | 11.8% (better) |
| FCF margin | 16.2% (better) | 1.9% |
| Return on equity | – | 9.7% |
| Return on invested capital | 26.2% (better) | 11.0% |
| Financial health | ||
| Net debt / EBITDA | 4.63 | – |
| Interest coverage | – | 8.8× |
| Current ratio | 1.68 | 1.76 (better) |
| Altman Z-score | 1.33 | – |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 5.0% | – |
| Payout ratio | 31.1% | 10.5% |
| Years of dividend growth | 0 | – |
| Shareholder yield | 5.0% | – |
| Ownership | ||
| Held by institutions | 88.9% | 15.0% |
| Held by insiders | 3.9% | 83.9% |
| Insider net buying, 12 months | $521K (better) | $39.4K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 10.7% | – |
Go deeper
- EMBC stock overview
- EMBC income statement
- EMBC valuation and score
- STVN stock overview
- STVN income statement
- STVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.